Autologous Stem Cell Transplantation for POEMS Syndrome

Slides:

Advertisements

Similar presentations

Distribution of Human Embryonic Stem Cell Lines: Who, When, and Where Jennifer B. McCormick, Jason Owen-Smith, Christopher Thomas Scott Cell Stem Cell.

Advertisements

Evolution of the Cancer Stem Cell Model Antonija Kreso, John E. Dick Cell Stem Cell Volume 14, Issue 3, Pages (March 2014) DOI: /j.stem

Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia Tim C.P. Somervaille, Michael L. Cleary Cancer Cell.

IPSC Crowdsourcing: A Model for Obtaining Large Panels of Stem Cell Lines for Screening Mahendra Rao Cell Stem Cell Volume 13, Issue 4, Pages (October.

Quantitative Single-Cell Approaches to Stem Cell Research Martin Etzrodt, Max Endele, Timm Schroeder Cell Stem Cell Volume 15, Issue 5, Pages (November.

Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group Fernando Franco Pérez, Javier Lavernia, David Aguiar-Bujanda, José.

Volume 20, Issue 2, (February 2012)

Divergent Effects of Novel Immunomodulatory Agents and Cyclophosphamide on the Risk of Engraftment Syndrome after Autologous Peripheral Blood Stem Cell.

The Prognostic Significance of Elevated Levels of Serum Ferritin Before Chemotherapy in Patients With Non-Hodgkin Lymphoma Kyung Ah Yoh, Ho Sup Lee,

Building better therapy for children with acute lymphoblastic leukemia

Primary Breast Lymphoma: Analysis of 55 Cases of the Spanish Lymphoma Oncology Group Fernando Franco Pérez, Javier Lavernia, David Aguiar-Bujanda, José.

VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study

Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with.

Multiple Myeloma: Diagnosis and Treatment

Nishitha M. Reddy, Olalekan Oluwole, John P. Greer, Brian G

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma Mehdi Hamadani, Erinn Hade, Don M. Benson,

Plerixafor Plus Granulocyte Colony-Stimulating Factor for Patients with Non-Hodgkin Lymphoma and Multiple Myeloma: Long-Term Follow-Up Report Ivana N.

Autologous Stem Cell Transplantation with Thiotepa, Busulfan, and Cyclophosphamide (TBC) Conditioning in Patients with CNS Involvement by Non-Hodgkin.

The Epidemiology and Clinical Associations of Stroke in Patients With Acute Myeloid Leukemia: A Review of 10,972 Admissions From the 2012 National Inpatient.

Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma,

Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI Alix O’Meara, Jörg Halter, Dominik.

Immune Reconstitution after Autologous Hematopoietic Cell Transplant (AHCT) in B-Cell Non-Hodgkin Lymphoma (B-NHL) Patients Mobilized with Granulocyte.

Limited Utility of Surveillance Imaging for Detecting Disease Relapse in Patients With Non-Hodgkin Lymphoma in First Complete Remission Quoc Truong,

Extracorporeal Photopheresis and Adjuvant Aerosolized Granulocyte-Macrophage Colony-Stimulating Factor for Sézary Syndrome Saskia A. Bouwhuis, MD, Svetomir.

A 15-Year Analysis of Early and Late Autologous Hematopoietic Stem Cell Transplant in Relapsed, Aggressive, Transformed, and Nontransformed Follicular.

A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B- cell Non-Hodgkin Lymphoma Pallawi Torka, Priyank Patel, Wei Tan,

Stem Cell Therapies in Clinical Trials: Progress and Challenges

Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with.

Reduced-Intensity Allogeneic Stem Cell Transplantation in Adults and Children with Malignant and Nonmalignant Diseases: End of the Beginning and Future.

A Comparison of Clofarabine-based (GCLAC) and Cladribine-based (CLAG) Salvage Chemotherapy for Relapsed/Refractory AML Benyam Muluneh, Kaitlyn Buhlinger,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Subepithelial Corneal Immunoglobulin Deposition as a Manifestation of Multiple Myeloma: A Case Report and Literature Review Trent P. Wang, Steven G.

Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience AnnaLynn M. Williams, Andrea M. Baran, Carla Casulo,

Interim Functional Imaging Is an Independent Predictor of Progression-free Survival in Advanced Classical Hodgkin Lymphoma – A Real-world Analysis Moussab.

Vascular Endothelial Growth Factor and Activin-A Serum Levels Following Allogeneic Hematopoietic Stem Cell Transplantation David Nachbaur, Petra Schumacher,

Multiple Myeloma in Serologic Complete Remission after Autologous Stem Cell Transplantation: Impact of Bone Marrow Plasma Cell Assessment by Conventional.

Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment- resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma Shumaila.

An expanded phase I/II trial of cyclophosphamide, etoposide, and carboplatin plus total body irradiation with autologous marrow or stem cell support for.

An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma John M. Burke,

Vertebral Fracture Risk of Multiple Myeloma Assessed by a CT-based Finite Element and Trabecular Structure Analysis Miyuki Takasu, Yoko Kaichi, Kazuo.

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

Hemophagocytic Lymphohistiocytosis in a Patient With Multiple Myeloma

Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation Vijaya.

The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.

Clinical Lymphoma, Myeloma and Leukemia

Single-Agent Liposomal All-Trans-Retinoic Acid as Initial Therapy for Acute Promyelocytic Leukemia: 13-Year Follow-Up Data Preetesh Jain, Hagop Kantarjian,

Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I Carole B. Miller, Rami S. Komrokji, Ruben A. Mesa,

Sarah A. Holstein, Paul G. Richardson, Jacob P. Laubach, Philip L

Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides Francine Foss, Madeleine Duvic, Adam Lerner, Joel Waksman, Sean Whittaker

Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma John Kuruvilla, Gregory Pond, Richard.

Kamal Kant Singh Abbi, Junting Zheng, Sean M

A Post Hoc Sensitivity Analysis of Survival Probabilities in a Multinational Phase III Trial of Decitabine in Older Patients With Newly Diagnosed Acute.

Efficacy of Thiotepa-Busulfan-Cyclophosphamide (TBC) Conditioning and Autologous Transplantation As Consolidation for Systemic Non-Hodgkin Lymphoma with.

A Comparison of Long-Term Outcomes of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors in Patients With Relapsed CML After Allogeneic Hematopoietic.

Elevated Ferritin Is Associated with Relapse after Autologous Hematopoietic Stem Cell Transplantation for Lymphoma Anuj Mahindra, Brian Bolwell, Ronald.

Prognostic Analysis of Absolute Lymphocyte and Monocyte Counts after Autologous Stem Cell Transplantation in Children, Adolescents, and Young Adults with.

Rituximab-Based Chemoimmunotherapy Prolongs Survival of Patients With Chronic Lymphocytic Leukemia Independently of the Time of Administration Julio.

Predictive and Prognostic Markers in Adults With Acute Myeloid Leukemia: A Single- Institution Experience Bolanle Gbadamosi, Daniel Ezekwudo, Sanjog Bastola,

Single Center Experience with High Dose Melphalan and Two Day Washout in Patients with Multiple Myeloma on Hemodialysis Undergoing Autologous Stem Cell.

Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma Stephen.

Challenges in Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)

Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival Victor H. Jimenez-Zepeda,

Phase II Study of Vincristine Sulfate Liposome Injection (Marqibo) and Rituximab for Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma.

Clinical Lymphoma, Myeloma and Leukemia

Pure Erythroid Leukemia Presenting in a HIV-Positive Patient

Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse

Early Lymphocyte Recovery Predicts Superior Survival after Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma: A Prospective Study Luis F.

Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma Ivan Aksentijevich,

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Presentation transcript:

Autologous Stem Cell Transplantation for POEMS Syndrome Chiaki Nakaseko Clinical Lymphoma, Myeloma and Leukemia Volume 14, Issue 1, Pages 21-23 (February 2014) DOI: 10.1016/j.clml.2013.12.009 Copyright © 2014 Elsevier Inc. Terms and Conditions

Figure 1 Efficiency of Stem Cell Mobilization in Patients With POEMS Syndrome. (A) Cyclophosphamide (CY) Plus Granulocyte Colony-Stimulating Factor (G-CSF). (B) G-CSF Alone Clinical Lymphoma, Myeloma and Leukemia 2014 14, 21-23DOI: (10.1016/j.clml.2013.12.009) Copyright © 2014 Elsevier Inc. Terms and Conditions

Figure 2 Overall Survival (OS) and Progression-Free Survival (PFS) After Autologous Stem Cell Transplantation. (A) OS. (B) PFS. Progression was Defined as Elevated Vascular Endothelial Growth Factor Level (≥ 1000 pg/mL) and/or Clinical Relapse Clinical Lymphoma, Myeloma and Leukemia 2014 14, 21-23DOI: (10.1016/j.clml.2013.12.009) Copyright © 2014 Elsevier Inc. Terms and Conditions